Cyclo-oxygenase-1 and cyclo-oxygenase-2 and cardiovascular system

Digestive and Liver Disease

Volumn 33, Issue SUPPL. 2, 2001, Pages

  Lettino, M ^a   Cantu F ^a   Mariani, M ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Aspirin; Atherosclerosis; Cyclo oxygenase; Endothelial cells; Platelets; Prostaglandin

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; ISOENZYME; PROSTAGLANDIN; TICLOPIDINE; TIROFIBAN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR SYSTEM; DRUG EFFECT; DRUG SELECTIVITY; ENDOTHELIUM CELL; FOAM CELL; HUMAN; MACROPHAGE; PATHOPHYSIOLOGY; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; THROMBOCYTE; THROMBOCYTE ACTIVATION;

EID: 0035674193     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(01)80154-7     Document Type: Article

References (39)

1. Prostacyclin and thromboxane synthases
2. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides
3. Isoprostanes: Potential markers of oxidant stress in atherothrombotic disease
4. Eicosanoids and iso-eicosanoids: Constitutive, inducible and transcellular biosynthesis in vascular disease
5. Cyclo-oxygenase-dependent formation of the isoprostane, 8-epi-prostaglandin F2alfa
6. The role of leukotrienes in inflammation
7. Prostanoid receptors. Structure, function and distribution
8. Physiological and pathophysiological roles of eicosanoids in the microcirculation
9. Eicosanoids in regulation of arterial smooth muscle cell phenotype, proliferative capacity, and cholesterol metabolism
10. Prostaglandins mediate arteriolar dilation to increased blood flow velocity in skeletal muscle microcirculation
11. Direct stimulation of limbal microvessel endothelial cell proliferation and capillary formation in vitro by a corneal derived eicosanoid
12. Pharmacology of prostaglandin endoperoxide synthase isozyme-1 and -2
13. Cyclo-oxygenase isoenzymes physiological and pharmacological role
14. Inducible cyclooxygenase and nitric oxide synthase
15. Regulation of the expression of cyclooxygenase-2 by nitric oxide in rat peritoneal macrophages
16. Endogenous nitric oxide enhances prostaglandin production in a model of renal inflammation
17. Nitric oxide produced by endothelial cells increases production of eicosanoids through the activation of prostaglandin H synthase
18. Nitric oxide activates cyclo-oxygenase enzymes
19. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles
20. The pathogenesis of atherosclerosis, a perspective for the 1990s
21. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions
22. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages
23. Antiplatelet drugs. A comparative review
24. Aspirin selectively inhibits prostaglandin production in human platelets
25. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate protein fraction
26. Prostaglandin endoperoxide synthase: The aspirin acetylation region
27. Aspirin and platelets: The antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis
28. Selective cumulative inhibition of platelet thromboxane production by low dose aspirin in healthy subjects
29. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients
30. Low-dose aspirin fails to inhibit increased platelet reactivity in patients with peripheral vascular disease
31. Aspirin dose in stroke prevention. Beautiful hypotheses slain by ugly facts
32. Platelet-active drugs. The relationship among dose, effectiveness, and side effects
33. Aspirin as an antiplatelet drug
34. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina
35. Increased shear stress overcomes the antithrombotic platelet inhibitory effect of aspirin in stenosed dog coronary arteries
36. Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy
37. Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers
38. Platelet activation mechanisms and markers in arterial thrombosis
39. Platelet activation and coronary stent implantation. Effect of antithrombotic therapy